GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.
Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.
According to a new study, the company returns results for more than 90 percent of its GeneStrat tests within 72 hours and aims to bring that down to 48 hours.
The test, which the company plans to launch later this year, will use MALDI-based proteomics to assess patients' likelihood of responding to immunotherapies.
Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.
The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.